IBIO News

IntraBio verkündet positive Ergebnisse der Zulassungsstudie für Levacetylleucin zur Behandlung von Ataxia-Telangiectasia

IntraBio annuncia i risultati positivi dello studio clinico pivotale sulla levacetilleucina nel trattamento dell'atassia-teleangectasia

IntraBio、毛細血管拡張性運動失調症（A-T）治療に向けたレバアセチルロイシンの主要第3相試験で良好な結果を発表

iBio Announces $26 Million Private Placement

Bioanalytical Services Market Projected to Reach US$ 11.61 Billion by 2035, Driven by Rising FDA Approvals and Clinical Trial Activity Says Astute Analytica

Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance